Skip to content

Author

T. Macarulla

We have 4 of 557 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

BACKGROUND AIMS To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy. APPROACH RESULTS Open-label, non-contro...

M. Borad, Michele Droz Dit Busset, M. Javle et al. · 0 citations
Sep 2026

Abstract PR014: Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer

KRAS G12D is a prevalent oncogenic driver in PDAC, which has a high unmet need due to few effective targeted therapies. Setidegrasib, a novel KRAS G12D-targeted protein degrader, eliminates the oncogenic driver to suppress downstream signaling and induce tumor cell death. Early clinical activity was reported in a...

W. Park, S. Kadam, A. Kasi et al. · 0 citations
#gene editing Review Sep 2026

Abstract A129: Phasic Hedgehog Inhibition Primes the Pancreatic Tumor Microenvironment to Enhance Chemoimmunotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: Results from the Phase 1b/2 NUMANTIA Trial

CAF-directed stromal priming as a strategy to enhance chemoimmunotherapy and warrant evaluation in randomized studies with integrated biomarker analyses are supported.

V. S. Kalluri, B. Bockorny, Evelio Perea Borobio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.